Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04945226
Other study ID # IVL3001-001
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date September 21, 2021
Est. completion date February 8, 2022

Study information

Verified date February 2022
Source Inventage Lab., Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001


Description:

A Randomized, Open-Label, Exploratory, Pharmacokinetic, Sequential Single Ascending dose Study of IVL3001 Versus Propecia (Finasteride) Tablets in Healthy Adult Participants


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date February 8, 2022
Est. primary completion date February 8, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - Healthy male, non-smoker or, if a moderate or occasional smoker (< 10 cigarettes per day or nicotine equivalent) must agree to abstain from smoking from 48 h before first IP administration through to completion of the final EOS/ET visit, aged = 18 to 55 years (inclusive at the time of informed consent) - In good general health, in the opinion of the Investigator, with no significant medical history, and have no clinically significant abnormalities on complete physical examination, 12-lead ECG, heart rate, and BP, both at Screening and before administration of the initial dose of IP - Body mass index (BMI) between = 18 kg/m2 and = 32 kg/m2 and a minimum weight = 50 kg and = 100 kg at Screening - Clinical laboratory values within normal limits, with normal range as specified by the testing laboratory, unless deemed not clinically significant by the Investigator or delegate - Ability and willingness to attend the necessary visits to the CRU and be domiciled overnight - Willing and able to provide written informed consent after the nature of the study has been explained and prior to the commencement of any protocol-specific study procedures Exclusion Criteria: - Prior or ongoing medical conditions, medical history, physical examination findings, or laboratory abnormalities that, in the Investigator's (or delegate's) opinion, could adversely affect the safety of the participant - Presence or history of any clinically significant blood, kidney, endocrine, lung, gastrointestinal tract, cardiovascular, liver, or neurological condition - Presence of any underlying physical or psychological (eg, depression) medical condition that, in the opinion of the Investigator, would make it unlikely that the participant will comply with the protocol or complete the study per protocol. Mild depression and anxiety that has been resolved at least 6-12 months ago is accepted. - Presence of any medical condition that may affect oral drug absorption (eg, gastrectomy, gall bladder removal, bariatric surgery, gastric bypass and sleeve, bowel resection) - Hypersensitivity to finasteride or to any excipient of the IPs - Age adjusted PSA between 0 2.5 ng/mL for subjects = 50 years of age and between 0-4 ng/mL for subjects > 50 years of age at Screening, unless deemed not clinically significant by the Investigator or delegate - History or known presence of any prostatic problem (infection, prostate cancer, stricture disease, hypotonic bladder or other neurogenic disorder that might mimic BPH) - Positive test for hepatitis C antibody (HCV), hepatitis B surface antigen (HBsAg), HIV antigen or antibody at Screening - Positive toxicology screening panel (urine test including qualitative identification of barbiturates, tetrahydrocannabinol [THC], amphetamines, benzodiazepines, opiates and cocaine), or a positive alcohol breath (or urine), or cotinine test - History of alcohol or substance abuse or dependency, or history of recreational intravenous (IV) drug use over the last 1 year (by self-declaration) - Regular alcohol consumption defined as > 21 alcohol units per week (where 1 unit = 284 mL of beer, 25 mL of 40% spirit, or a 125 mL glass of wine) within 6 months of Screening. - Use of any IP or investigational medical device within 3 months prior to Screening, or five half-lives of the product (whichever is the longest), or participation in more than 4 investigational drug studies within 1 year prior to Screening - Use of any drug known to significantly induce or inhibit drug absorption or metabolism within 30 days prior to dosing - An employee, or relative of an employee, directly involved in the conduct of the study - Unwilling to refrain from strenuous exercise from 48 hours prior to admission to the CRU at Day -1 and 48 hours prior to each follow-up - Presence of sexual dysfunction such as decreased libido, erectile dysfunction, or ejaculation disorder - Estimated glomerular filtration rate (eGFR) < 90 mL/min/1.73m2 at Screening - Any reason which, in the opinion of the PI, would prevent the subject from participating in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Finasteride 1mg Tablet
Propecia Tablet 1mg
IVL3001
Finasteride long acting injection

Locations

Country Name City State
Australia Nucleus Network Brisbane

Sponsors (1)

Lead Sponsor Collaborator
Inventage Lab., Inc.

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary AUClast of IVL3001 Area under the concentration-time curve from time zero to last Pre-dose, 1008 hours
Primary AUCinf of IVL3001 Area under the concentration-time curve from time zero to infinity Pre-dose, 1008 hours
Primary AUC0-1008h of IVL3001 Area under the concentration-time curve from time zero to 1008 hours Pre-dose, 1008 hours
Primary AUClast of Propecia Area under the concentration-time curve from time zero to last Pre-dose, 816 hours
Primary AUCinf of Propecia Area under the concentration-time curve from time zero to infinity Pre-dose, 816 hours
Primary AUC0-672h of Propecia Area under the concentration-time curve from time zero to 672hours Pre-dose, 672 hours
See also
  Status Clinical Trial Phase
Completed NCT02591355 - Evaluate the Clinical Effectiveness of RegenKit Platelet-rich Plasma (PRP) in Androgenetic Alopecia Treatment N/A
Withdrawn NCT03852992 - Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia Phase 2
Recruiting NCT06239207 - Efficacy and Safety of Exosomes Versus Platelet Rich Plasma in Patients of Androgenetic Alopecia Phase 2
Completed NCT01437163 - Treatment of Androgenetic Alopecia in Males and Females N/A
Completed NCT01548066 - The Efficacy and Safety of Topical Valproic Acid in Preventing Hair Loss Phase 2
Completed NCT01226459 - Clinical Trial in Females for Female Pattern Hair Loss Phase 3
Recruiting NCT06118866 - A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia Phase 2
Completed NCT06149221 - Penetration-enhanced Direct DBD Non-thermal Plasma for Hair Loss N/A
Withdrawn NCT04882969 - Thulium Laser and KeraFactor for the Treatment of Androgenetic Alopecia N/A
Completed NCT01231607 - Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia Phase 3
Completed NCT04446429 - Anti-Androgen Treatment for COVID-19 N/A
Completed NCT02729415 - Point-of-Care Adipose-derived Cells for Hair Growth N/A
Completed NCT02279823 - A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia Phase 2
Not yet recruiting NCT01227031 - Pharmacogenomic Study of Androgenetic Alopecia N/A
Completed NCT00981461 - Treatment of Androgenetic Alopecia in Females, 9 Beam N/A
Completed NCT01451021 - A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss Phase 2
Completed NCT00151515 - A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss Phase 3
Completed NCT03694067 - Androgenetic Alopecia and the JAK-STAT Pathway
Completed NCT03689452 - The Effect of Platelet Rich Plasma on Non-scarring Alopecia N/A
Completed NCT03753113 - Evaluating the Topical Herbal Solution on the Treatment of Male Pattern Hair Loss and Comparison With Minoxidil 5% Phase 3